CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 16 enrolled
Drug / intervention
atorvastatin +1 moredrug
Likely dose
atorvastatin 40mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00751907
NCT00751907Phase 2Completed
CompareCT.gov

Impact of Atorvastatin on Cerebral Perfusion and Endothelial Function

University of Wisconsin, Madison·interventional·Posted Sep 12, 2008·Updated Sep 9, 2019

In Brief

A Phase 2 clinical trial evaluating atorvastatin and Placebo for Alzheimer's Disease. Completed, enrolled 16 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the hypothesis that in middle-aged, asymptomatic, adult children of persons with Alzheimer's disease (AD), atorvastatin therapy will beneficially affect mechanisms thought to contribute to AD risk by improving blood flow in the brain, improving cerebral perfusion, increasing brain activity patterns, and improving blood vessel function.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesUnited States
CollaboratorsNational Institute on Aging (NIA)

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 12, 2008
Enrollment StartJun 1, 2006
Primary CompletionApr 1, 2007
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 17.8 years ago

Interventions

atorvastatindrug

40mg daily for 4 months

Placebodrug

Matching placebo daily for 4 months